Squamous Cell Carcinoma (original) (raw)
Latest News for: squamous cell carcinoma
Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma (Agilent Technologies Inc)
Public Technologies 02 Jun 2026
Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma.
ASCO 2026 Poster Presentation: A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: FORTIFI-HN01 (Bicara Therapeutics Inc)
Public Technologies 30 May 2026
). The text version of this document is not available ... Attachments Permalink. Disclaimer.
ASCO 2026 Poster Presentation: The impact of depth of response on long-term clinical outcomes: Exploratory analyses from multiple expansion cohorts of a phase 1/1b study of ficerafusp alfa plus pembrolizumab in first-line recurrent/metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC) (Bicara Therapeutics Inc)
Public Technologies 30 May 2026
). The text version of this document is not available ... Attachments Permalink. Disclaimer.
ASCO 2026 Poster Presentation: Sustained depth and durability of response with TGF-β trapping in recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC): Long-term results from two expansion cohorts of a phase 1/1b study of ficerafusp alfa plus pembrolizumab (Bicara Therapeutics Inc)
Public Technologies 30 May 2026
). The text version of this document is not available ... Attachments Permalink. Disclaimer.
Head and Neck Squamous Cell Carcinomas Market Set for Robust Expansion Through 2036, DelveInsight Reports ...
GetNews 29 May 2026
DelveInsight’s “Head and Neck Squamous Cell Carcinomas Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Head and Neck Squamous ...
SkylineDx to Showcase New Cutaneous Squamous Cell Carcinoma Findings at 83rd Society for Investigative Dermatology Annual Meeting
PR Newswire 12 May 2026
A novel gene-expression signature for cutaneous squamous cell carcinoma demonstrates the ability to identify patients with a higher risk of developing metastasis, outperforming existing staging systems.
Journal of Clinical Oncology: Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase 1/1b Trial (Bicara Therapeutics Inc)
Public Technologies 09 May 2026
Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma ... PURPOSE Patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M ...
Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma (Form 6-K) (Alpha Tau Medical Ltd)
Public Technologies 08 May 2026
Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma ... patients with recurrent cutaneous squamous cell carcinoma (cSCC).
Cutaneous Squamous Cell Carcinoma Clinical Trial Pipeline Appears Robust With 45+ Key Pharma Companies Actively ...
GetNews 29 Apr 2026
Inactive Products Cutaneous Squamous Cell Carcinoma Key Companies Cutaneous Squamous Cell Carcinoma Key Products Cutaneous Squamous Cell Carcinoma- Unmet Needs Cutaneous Squamous Cell Carcinoma- ...
EIU-104101: A first-in-human phase 1a/1b study of EVOLVE104, a trispecific CD3×CD2×ULBP2/5/6 T cell engager, in advanced urothelial and squamous cell carcinomas (AACR2026 EIU 104101 TiP final) (EvolveImmune Therapeutics Holding Co LLC)
Public Technologies 25 Apr 2026
A first-in-human phase 1a/1b study of EVOLVE104, a trispecific CD3×CD2×ULBP2/5/6 T cell engager, in advanced urothelial and squamous cell carcinomas ... Cell surface ULBP2/5/6 is found in urothelial carcinomas and squamous cell carcinomas (SCCs).
SkylineDx to Present Data on Precision Molecular Diagnostics Advances in Cutaneous Squamous Cell Carcinoma at 22nd EADO Congress
PR Newswire 23 Apr 2026
New gene-signature for cutaneous squamous cell carcinoma (CSCC) demonstrates ability to identify a subset of patients with higher risk of developing metastasis, outperforming existing staging systems ... Cutaneous squamous cell carcinoma.
WWOX maintains epidermal identity and suppresses EMT to prevent aggressive cutaneous squamous cell carcinoma
PNAS 15 Apr 2026
SignificanceCutaneous squamous cell carcinoma (cSCC) is an ...
Head and Neck Squamous Cell Carcinomas Market: Rapid Increment Driven by Innovation by 2034 – ...
GetNews 10 Apr 2026
DelveInsight’s “Head and Neck Squamous Cell Carcinomas Patient Pool Analysis, Market Size and Market Forecast APAC - 2034″ report offers an in-depth understanding of the Head and ...
Head and Neck Squamous Cell Carcinoma Market Forecast to 2030 & 2035
Nasdaq Globe Newswire 02 Apr 2026
Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Head and ...
Cutaneous Squamous Cell Carcinoma (cSCC) Market Rises to $8.33 Billion in 2026: Roche, Merck & ...
Nasdaq Globe Newswire 30 Mar 2026
Major players are focusing on immuno-oncology advancements ... .